204 related articles for article (PubMed ID: 16012011)
1. In vitro susceptibility of quinolone-resistant Enterobacteriaceae uropathogens to fosfomycin trometamol, in Dakar, Senegal.
Nabeth P; Perrier-Gros-Claude JD; Juergens-Behr A; Dromigny JA
Scand J Infect Dis; 2005; 37(6-7):497-9. PubMed ID: 16012011
[TBL] [Abstract][Full Text] [Related]
2. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
Garau J
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
[TBL] [Abstract][Full Text] [Related]
3. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.
Muratani T; Matsumoto T
Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S10-3. PubMed ID: 16829056
[TBL] [Abstract][Full Text] [Related]
4.
Sahu M; Saseedharan S; Bhalekar P
Indian J Med Microbiol; 2017; 35(3):437-438. PubMed ID: 29063896
[No Abstract] [Full Text] [Related]
5. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol.
Ungheri D; Albini E; Belluco G
J Chemother; 2002 Jun; 14(3):237-40. PubMed ID: 12120876
[TBL] [Abstract][Full Text] [Related]
6. Fosfomycin: an oral agent for urinary infection caused by extended spectrum beta-lactamase producing organisms.
Hutley EJ; Chand MA; Hounsome G; Kelsey MC
J Infect; 2010 Apr; 60(4):308-9. PubMed ID: 20114062
[No Abstract] [Full Text] [Related]
7. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
[TBL] [Abstract][Full Text] [Related]
8. Plasmid-mediated quinolone resistance genes in Enterobacteriaceae isolates associated with community and nosocomial urinary tract infection in East London, UK.
Amin AK; Wareham DW
Int J Antimicrob Agents; 2009 Nov; 34(5):490-1. PubMed ID: 19261447
[No Abstract] [Full Text] [Related]
9. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents.
Hsu MS; Liao CH; Liu CY; Yang CJ; Huang YT; Hsueh PR
Int J Antimicrob Agents; 2011 Mar; 37(3):276-8. PubMed ID: 21269811
[No Abstract] [Full Text] [Related]
10. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10.
Pogue JM; Marchaim D; Abreu-Lanfranco O; Sunkara B; Mynatt RP; Zhao JJ; Bheemreddy S; Hayakawa K; Martin ET; Dhar S; Kaye KS; Lephart PR
J Antibiot (Tokyo); 2013 Oct; 66(10):625-7. PubMed ID: 23715037
[No Abstract] [Full Text] [Related]
11. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
[TBL] [Abstract][Full Text] [Related]
13. Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe.
Guyomard-Rabenirina S; Malespine J; Ducat C; Sadikalay S; Falord M; Harrois D; Richard V; Dozois C; ; Breurec S; Talarmin A
BMC Microbiol; 2016 Jun; 16(1):121. PubMed ID: 27342199
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: results of an Italian multicenter survey.
Schito GC; Chezzi C; Nicoletti G; Moreddu M; Arcangeletti MC; Stefani S; Albini E; Del Bono GP
Infection; 1992; 20 Suppl 4():S291-5. PubMed ID: 1294520
[TBL] [Abstract][Full Text] [Related]
15. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar.
Randrianirina F; Soares JL; Carod JF; Ratsima E; Thonnier V; Combe P; Grosjean P; Talarmin A
J Antimicrob Chemother; 2007 Feb; 59(2):309-12. PubMed ID: 17138569
[TBL] [Abstract][Full Text] [Related]
17. Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Dakar, Senegal: a multicenter study.
Dromigny JA; Ndoye B; Macondo EA; Nabeth P; Siby T; Perrier-Gros-Claude JD
Diagn Microbiol Infect Dis; 2003 Dec; 47(4):595-600. PubMed ID: 14711481
[TBL] [Abstract][Full Text] [Related]
18. Resistance to oral antibiotics in urinary coliform strains isolated between 2000 and 2008 in Sønderborg area, Denmark.
Cybulski Z; Kjaeldgaard P
Int J Antimicrob Agents; 2010 May; 35(5):516-7. PubMed ID: 20202798
[No Abstract] [Full Text] [Related]
19. Antibiotic resistance of coliform organisms from community-acquired urinary tract infections in Zenica-Doboj Canton, Bosnia and Herzegovina.
Uzunovic-Kamberovic S
J Antimicrob Chemother; 2006 Aug; 58(2):344-8. PubMed ID: 16775214
[TBL] [Abstract][Full Text] [Related]
20. Appearance of fosfomycin resistant Rahnella aquatilis clinically isolated in Japan.
O'Hara K; Chen J; Shigenobu F; Nakamura A; Taniguchi K; Shimojima M; Ida H; Yoshikawa E; Tsuboi I; Mizuoka K; Sawai T
Microbios; 1998; 95(381):109-15. PubMed ID: 9872000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
